Correlation Study of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) on Diabetic Patients with Hypertension
Abstract
Background: To investigate the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on blood pressure, blood glucose and blood lipid in diabetic patients with hypertension.
Methods: A total of 300 diabetic patients and essential hypertension admitted to our hospital from January 2021 to December 2022 were selected, and divided into an observation group and a control group using a random number table method. The control group was treated with conventional antihypertensive drugs, hypoglycemic drugs, and lipid-lowering drugs. The observation group was supplemented with liraglutide on the basis of the control group. Blood pressure, blood glucose and blood lipid of the two groups were compared at the initial stage of medication and after 4 weeks and half a year, and the influencing factors of patients with persistent hypertension were further analyzed through Logistic regression.
Results: After 4 weeks and 6 months of medication, inter group comparisons showed that systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting blood glucose (FBG) and glycated hemoglobin (HbA1c), as well as total cholesterol (TC), triacylglycerol (TG), and plasma arteriosclerosis index (AIP) in the observation group were significantly lower than those in the control group (Ρ <0.05). Multivariate Logistic regression model analysis showed that age, smoking history, drinking history, taking conventional antihypertensive drugs, taking hypoglycemic drugs, taking lipid-lowering drugs, BMI, FBG, HbA1c and LDL-C were independent influencing factors for persistent hypertension (Ρ<0.05).
Conclusion: GLP-1RAs can effectively improve the indexes including blood pressure, blood glucose and blood lipid in diabetic patients with hypertension.
2. Shrestha P, Kaiti R, Shyangbo R (2022). Blindness among Patients with Type II Diabetes Mellitus Presenting to the Out-patient Department of Ophthalmology of a Tertiary Care Centre: A Descriptive Cross-sectional Study. JNMA J Nepal Med Assoc, 60(254): 877-880.
3. Deerochanawong C, Chan SP, Matawaran BJ, et al (2019). Use of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus and multi-ple cardiovascular risk factors: An Asian perspective and expert recommenda-tions. Diabetes Obes Metab, 21: 2354-2367.
4. Jia W, Weng J, Zhu D, et al (2019). Standards of medical care for type 2 diabetes in China 2019. Diabetes Metab Res Rev, 35(6): e3158.
5. Gilbert MP, Pratley RE (2020). GLP-1 Ana-logs and DPP-4 Inhibitors in Type 2 Di-abetes Therapy: Review of Head-to-Head Clinical Trials. Front Endocrinol (Lausanne), 11:178.
6. Franch-Nadal J, Granado-Casas M, Mata-Cases M, Ortega E, Vlacho B, Mauricio D (2022). Determinants of response to the glucagon-like peptide-1 receptor ag-onists in a type 2 diabetes population in the real-world. Prim Care Diabetes, 16: 810-817.
7. Kelkar A, Kelkar J, Mehta H, Amoaku W (2018). Cataract surgery in diabetes mellitus: A systematic review. Indian J Ophthalmol, 66(10): 1401-1410.
8. Howse PM, Chibrikova LN, Twells LK, Bar-rett BJ, Gamble JM (2016). Safety and Efficacy of Incretin-Based Therapies in Patients with Type 2 Diabetes Mellitus and CKD: A Systematic Review and Me-ta-analysis. Am J Kidney Dis, 68: 733-742.
9. Jensterle M, Rizzo M, Haluzík M, Janež A (2022). Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review. Adv Ther, 39(6): 2452-2467.
10. Cheng Z, Zhang M, Hu J, et al (2018). Mst1 knockout enhances cardiomyocyte au-tophagic flux to alleviate angiotensin II-induced cardiac injury independent of angiotensin II receptors. J Mol Cell Cardi-ol, 125: 117-128.
11. Mathey CM, Maj C, Scheer AB, et al (2022). Molecular Genetic Screening in Patients With ACE Inhibitor/Angiotensin Re-ceptor Blocker-Induced Angioedema to Explore the Role of Hereditary Angi-oedema Genes. Front Genet, 13: 914376.
12. Holst JJ, McGill MA. (2012). Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid se-questrants. Clin Drug Investig, 32(1): 1-14.
13. Gu Y, Sun L, Zhang W, et al (2023). Com-parative efficacy of 5 sodium-glucose cotransporter protein-2 (SGLT-2) inhibi-tor and 4 glucagon-like peptide-1 (GLP-1) receptor agonist drugs in non-alcoholic fatty liver disease: A GRADE-assessed systematic review and network meta-analysis of randomized controlled trials. Front Pharmacol, 14: 1102792.
14. Zhu Y, Xu J, Zhang D, et al (2021). Efficacy and Safety of GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne), 12: 769069.
15. Nauck MA, Quast DR, Wefers J, Meier JJ (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab, 46: 101102.
16. Zhang X, Yip TC, Tse YK, et al (2023). Trends in risk factor control and treat-ment among patients with non-alcoholic fatty liver disease and type 2 diabetes between 2000 and 2020: A territory-wide study. Aliment Pharmacol Ther, 57: 1103-1116.
| Files | ||
| Issue | Vol 53 No 7 (2024) | |
| Section | Original Article(s) | |
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
